论文部分内容阅读
动脉粥样硬化最严重的后果之一是血栓形成。已知组织因子是血栓形成的起始因子,组织因子途径抑制物-1是组织因子的生理抑制剂,组织因子途径抑制物-2能抑制细胞外基质降解。通过分子改造,研制出重组人源性长效组织因子途径抑制物(rhlTFPI),其不仅能对抗动脉粥样硬化并发的血栓形成,而且能抑制内膜的增生。探讨rhlTFPI与斑块的稳定性及组织因子途径抑制物-2与细胞外基质降解关系,具有重要的理论意义;有助于今后应用rhlTFPI和重组组织因子途径抑制物-2维持斑块稳定、防治动脉粥样硬化疾病。
One of the most serious consequences of atherosclerosis is thrombosis. Tissue factor is known as an initiating factor for thrombosis. Tissue factor pathway inhibitor-1 is a physiological inhibitor of tissue factor and tissue factor pathway inhibitor-2 inhibits extracellular matrix degradation. Through molecular modification, a recombinant human long-acting inhibitor of rhIL-TFPI (rhlTFPI) was developed, which can not only resist the thrombosis of atherosclerosis, but also inhibit the proliferation of the intima. To investigate the relationship between the stability of rhlTFPI and plaque and the relationship between tissue factor pathway inhibitor-2 and extracellular matrix degradation is of great theoretical significance; it is helpful for the future application of rhlTFPI and recombinant tissue factor pathway inhibitor-2 to maintain plaque stability and prevention and treatment Atherosclerosis disease.